BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35271670)

  • 21. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.
    Xing H; Zheng YJ; Han J; Zhang H; Li ZL; Lau WY; Shen F; Yang T
    Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):487-495. PubMed ID: 30257796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
    Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of protein induced by absence of vitamin K absence or antagonist II, alpha-fetoprotein and gamma-glutamyltransferase/aspartate aminotransferase ratio for the diagnosis of hepatocellular carcinoma in transplantation candidates.
    Ekmen N; Akalin Ç; Akyildiz M
    Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):294-299. PubMed ID: 32796360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormal prothrombin: evaluation as a tumour marker and localization in tissues of patients with hepatocellular carcinoma.
    Koda T; Yamazaki S; Tamura I; Nakaba H; Takao T; Katayama S; Kurimura O
    J Gastroenterol Hepatol; 1993; 8(3):212-6. PubMed ID: 7686054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data.
    Yu R; Tan Z; Xiang X; Dan Y; Deng G
    BMC Cancer; 2017 Sep; 17(1):608. PubMed ID: 28863782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
    Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
    Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
    World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma.
    Chen J; Tang D; Xu C; Niu Z; Li H; Li Y; Zhang P
    Lab Med; 2021 Jul; 52(4):381-389. PubMed ID: 33159511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma].
    Zhang JW; Guan LY; E CY; Yang JH; Xuan W; Meng ZH; Li W
    Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):776-781. PubMed ID: 32993265
    [No Abstract]   [Full Text] [Related]  

  • 32. Acarboxy prothrombin (PIVKA-II) as a marker of hepatoblastoma in infants.
    Motohara K; Endo F; Matsuda I; Iwamasa T
    J Pediatr Gastroenterol Nutr; 1987; 6(1):42-5. PubMed ID: 2432210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
    Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
    Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma.
    Grosley BM; Hirschauer C; Chambrette B; Bezeaud A; Amiral J
    J Lab Clin Med; 1996 Jun; 127(6):553-64. PubMed ID: 8648260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S; Morishita T; Shibata J; Sato T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.
    Ji J; Liu L; Jiang F; Wen X; Zhang Y; Li S; Lou J; Wang Y; Liu N; Guo Q; Jia Y; Gao C
    J Clin Lab Anal; 2021 Nov; 35(11):e24013. PubMed ID: 34590755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
    Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.